The Amyloid-β Pathway in Alzheimer’s Disease
Амилоид-β-путь при болезни Альцгеймера
2021-08-29
SCID: 54.1/cvv6hd8v
Discuss with AI
Alzheimer’s diseaseAβ dyshomeostasisAβ-targeting therapiesamyloid-β pathwaymultimodal biomarkers
Figures from the paper
Abstract (AI)
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for Aβ-targeting therapeutic strategies in development for the early treatment of AD.
Key Findings
1
Although the molecular and spatiotemporal mechanisms linking Aβ alterations to synaptic failure and neurodegeneration remain incompletely resolved, Aβ-targeting strategies are supported for early Alzheimer’s treatment.
2
Basic research, human genetic studies, and multimodal biomarker evidence support a crucial role for Aβ pathway dyshomeostasis in Alzheimer’s pathophysiology.
3
Distinct Aβ species interact differentially with tau-mediated processes, neuroimmune and inflammatory changes, and neurochemical imbalance.
4
The amyloid-β (Aβ) pathway is identified as a central biological hallmark of Alzheimer’s disease and a promising target for disease-modifying therapies.
Research Object
the amyloid-β (Aβ) pathway in Alzheimer’s disease
Research Subject
the pathway’s biochemical dyshomeostasis, molecular dynamics, and interactions with tau, neuroimmune and inflammatory mechanisms, and neurochemical balance in AD pathophysiology
Publication Details
Publication Date
2021-08-29
Journal
Publisher
ISSN
Cited by
2011
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest